NMES During the Day and Prior to Sleep

The Effect of Neuromuscular Electrical Stimulation on Post-prandial Protein Accretion During the Day and Prior to Sleep

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02253329

Acronym

ESPRO2

Enrollment

Registered

2014-10-01

Start date

2015-01-31

Completion date

2015-05-31

Last updated

2015-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcopenia

Keywords

Neuromuscular electrical stimulation, Ageing, Protein ingestion

Brief summary

In the present study, the effect of a bolus of intrinsically labeled milk directly after one-legged NMES (Neuromuscular Electrical Stimulation) will be studied under two conditions: during the day and prior to sleep

Detailed description

In the present study, the effect of a bolus of intrinsically labeled milk directly after an hour of one-legged NMES (Neuromuscular Electrical Stimulation) will be studied under two conditions: during the day and immediately prior to sleep

Interventions

PROCEDUREDietary protein plus NMES during the day

Neuromuscular electrical stimulation after a protein bolus, performed during the day

PROCEDUREDietary protein plus NMES prior to sleep

Neuromuscular electrical stimulation after a protein bolus, performed prior to sleep

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

65 Years to 85 Years

Healthy volunteers

Yes

Inclusion criteria

* Age 65-85 years * Male * 18.5 ≤ BMI ≤ 30.0

Exclusion criteria

* Type II diabetes * All co morbidities interacting with mobility and muscle metabolism of the lower limbs (e.g. arthrosis, arthritis, spasticity/rigidity, all neurological disorders, paralysis, hip/knee surgery). * Use of anticoagulants, blood diseases, allergy for lidocaine * Use of NSAIDs (non-steroidal anti-inflammatory drugs) and acetylsalicylic acid * Patients suffering from PKU (Phenylketonuria) * Presence of implantable cardioverter defibrillator and/or pacemaker * Performed regular resistance type exercise in the past 6 months * Use of any tools to assist during walking (cane/ crutches/ walker) * (Partial) foot/ leg amputation

Design outcomes

Primary

Measure	Time frame
Incorporation of stable isotope amino acids into skeletal muscle tissue	4-8 hours in the postprandial phase

Secondary

Measure	Time frame
Plasma amino acid enrichment	4-8 hours in the postprandial phase

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026